Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressive MS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never using a validated definition.
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis / Brown, J.W.L., Coles, A., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Trojano, M., Lugaresi, A., Bergamaschi, R., Grammond, P., Alroughani, R., Hupperts, R., Mccombe, P., Van Pesch, V., Sola, P., Ferraro, D., Grand'Maison, F., Terzi, M., et al.. - In: JAMA. - ISSN 0098-7484. - 321:2(2019), pp. 175-187. [10.1001/jama.2018.20588]
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
Ferraro, Diana;
2019
Abstract
Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressive MS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never using a validated definition.
| File | Dimensione | Formato | |
|---|---|---|---|
|
jama_brown_2019_oi_180152.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Licenza:
[IR] closed
Dimensione
626.05 kB
Formato
Adobe PDF
|
626.05 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
